Skip to content

Welcome to Discover Pharma! Today is : October 21, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

mental health

  • Digital & Data,Pharmaceuticals and therapeutics,Therapeutic Areas

    Tris Pharma partners with Calm Health and ADHD Central to support patients

    Tris Pharma has announced partnerships with Calm Health and ADHD [...]

    August 14, 2026
  • Central Nervous System,Research & Development

    Brain network dynamics may better explain psychiatric symptoms than diagnoses

    Rutgers researchers found that changes in brain network dynamics were [...]

    July 22, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development

    Compass Pathways study explores monitoring and support in COMP360 PTSD trial

    Compass Pathways has published a post hoc analysis of its [...]

    July 17, 2026
  • Clinical & Regulatory,Research & Development,Therapeutic Areas

    PET imaging reveals widespread synaptic loss in schizophrenia

    Advanced positron emission tomography (PET) imaging has revealed widespread loss [...]

    July 15, 2026
  • Biotech & Pharma Business,Central Nervous System

    Alto Neuroscience raises $100M to expand Phase 3 treatment-resistant depression programme

    Alto Neuroscience has raised $100 million through an underwritten registered [...]

    July 15, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    Compass reports second positive Phase 3 trial of psilocybin therapy for treatment-resistant depression

    Compass Pathways has reported positive six-month results from its second [...]

    July 8, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Compass Pathways reports positive second Phase 3 trial for COMP360 in treatment-resistant depression

    Compass Pathways has reported that its second pivotal Phase 3 [...]

    May 5, 2026
  • Opinion & Events,Pharmaceuticals and therapeutics,Therapeutic Areas

    Every day is a balancing act: One Mum’s journey raising a daughter with Type 1 diabetes

    This is a disease awareness paid article sponsored by Sanofi. [...]

    May 5, 2026
  • Central Nervous System,Clinical & Regulatory,Drug Discovery & Development

    Alto Neuroscience receives FDA Fast Track designation for ALTO-101 to treat cognitive impairment in schizophrenia

    Alto Neuroscience has received FDA Fast Track designation for its [...]

    May 5, 2026
  • Biotech & Pharma Business,Central Nervous System,Clinical & Regulatory,Opinion & Events,Pharmaceuticals and therapeutics

    Bristol Myers Squibb to launch Cobenfy in the UK at US list price for adults with schizophrenia

    Bristol Myers Squibb plans to launch Cobenfy (xanomeline and trospium [...]

    May 5, 2026
12Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Olink assay correlates with ELISA for measuring endothelin-1
    Categories: Clinical & Regulatory, Research & Development
  • BridgeBio gets FDA Priority Review for oral infigratinib in achondroplasia
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • ViiV’s Cabenuva achieves superior viral suppression in CROWN Phase 3b study
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top